Hot Pursuit     18-Jan-25
Gland Pharma gets EIR from USFDA for Pashamylaram facility
Gland Pharma announced that it has received an establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Pashamylaram facility at Hyderabad.
The Pashamylaram facility received an EIR, which indicates closure of the inspection, Gland Pharma said in a filing.

The USFDA inspected the facility between 25 July 2024 and 2 August 2024 for good manufacturing practices (GMP) and issued three Form 483 observations. These observations were procedural in nature.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

On a consolidated basis, the firm’s net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.10% to settle at Rs 1,678.95 on Friday, 18 January 2025.

Previous News
  Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
 ( Hot Pursuit - 12-Jul-25   12:27 )
  Nifty trades above 24,550 mark; realty shares declined
 ( Market Commentary - Mid-Session 04-Jun-25   10:36 )
  Gland Pharma gets US FDA approval for hypotension treatment drug Angiotensin II
 ( Hot Pursuit - 04-Jun-25   09:20 )
  Tilaknagar Industries Ltd leads gainers in 'A' group
 ( Hot Pursuit - 05-Nov-24   12:00 )
  Gland Pharma receives USFDA approval for Angiotensin II Acetate Injection 2.5 mg/mL
 ( Corporate News - 04-Jun-25   09:06 )
  Nifty slides below 23,950; pharma shares decline for 2nd day
 ( Market Commentary - Mid-Session 05-Nov-24   11:34 )
  Volumes jump at Gland Pharma Ltd counter
 ( Hot Pursuit - 05-Nov-24   11:00 )
  Gland Pharma allots 6,200 equity shares under ESOS
 ( Corporate News - 14-Feb-24   15:10 )
  Gland Pharma's Pashamylaram unit completes USFDA inspection
 ( Corporate News - 18-Jan-25   11:36 )
  Gland Pharma soars as Q2 PAT rises 9% QoQ to Rs 282 cr
 ( Hot Pursuit - 05-Nov-24   10:42 )
  Gland Pharma receives USFDA tentative approval for Angiotensin II Injection
 ( Corporate News - 15-Nov-23   11:42 )
Other Stories
  Zaggle Prepaid gains on inking pact with Tyger Capital
  17-Jul-25   15:24
  Navkar Corporation gains on reporting turnaround PAT of Rs 2 crore in Q1
  17-Jul-25   15:22
  HDFC AMC rallies after Q1 PAT jumps 24% YoY to Rs 748 cr
  17-Jul-25   15:12
  Newgen Software Technologies Ltd leads losers in 'A' group
  17-Jul-25   15:00
  Jayaswal Neco Industries Ltd leads losers in 'B' group
  17-Jul-25   14:45
  Volumes jump at Thermax Ltd counter
  17-Jul-25   14:30
  Newgen Software slumps after PAT drops over 54% YoY to Rs 49 crore
  17-Jul-25   14:23
  Mahindra Logistics spurts on disclosing rights issue details
  17-Jul-25   14:18
  Hexaware Tech edges higher after inking deal to acquire GCC building firm SMC Squared
  17-Jul-25   13:54
  Thermax Ltd soars 10.6%, up for third straight session
  17-Jul-25   13:05
Back Top